<code id='8E2D472A79'></code><style id='8E2D472A79'></style>
    • <acronym id='8E2D472A79'></acronym>
      <center id='8E2D472A79'><center id='8E2D472A79'><tfoot id='8E2D472A79'></tfoot></center><abbr id='8E2D472A79'><dir id='8E2D472A79'><tfoot id='8E2D472A79'></tfoot><noframes id='8E2D472A79'>

    • <optgroup id='8E2D472A79'><strike id='8E2D472A79'><sup id='8E2D472A79'></sup></strike><code id='8E2D472A79'></code></optgroup>
        1. <b id='8E2D472A79'><label id='8E2D472A79'><select id='8E2D472A79'><dt id='8E2D472A79'><span id='8E2D472A79'></span></dt></select></label></b><u id='8E2D472A79'></u>
          <i id='8E2D472A79'><strike id='8E2D472A79'><tt id='8E2D472A79'><pre id='8E2D472A79'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:fashion    Page View:29542
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In